Regeneron Pharmaceuticals (REGN) Capital Expenditures (2009 - 2026)

Regeneron Pharmaceuticals' Capital Expenditures history runs 18 years deep, the most recent figure standing at $230.6 million for Q1 2026.

• In Q1 2026, Capital Expenditures rose 0.57% year-over-year to $230.6 million; the TTM figure through Mar 2026 stood at $899.7 million (up 5.69% YoY), while the FY2025 annual figure was $898.4 million, up 18.85% from the prior year.
• Capital Expenditures was $230.6 million for Q1 2026 at Regeneron Pharmaceuticals, down from $248.7 million in the prior quarter.
• In the past five years, Capital Expenditures ranged from a high of $470.9 million in Q3 2025 to a low of -$102.8 million in Q2 2023.
• Historically, Capital Expenditures has averaged $187.9 million across 5 years, with a median of $178.2 million in 2023.
• The sharpest annual moves came in 2023 and 2025: Capital Expenditures jumped 174.95% in 2023, then sank 385.31% in 2025.
• A 5-year view of Capital Expenditures shows it stood at $152.2 million in 2022, then surged by 65.18% to $251.4 million in 2023, then dropped by 20.6% to $199.6 million in 2024, then rose by 24.6% to $248.7 million in 2025, then declined by 7.28% to $230.6 million in 2026.
• The last three Capital Expenditures figures came in at $230.6 million (Q1 2026), $248.7 million (Q4 2025), and $470.9 million (Q3 2025), per Business Quant data.